The future of DAAs in pediatrics looks promising, with ongoing research aimed at expanding the use of these drugs to younger age groups and other viral infections. Advances in pharmacogenomics may also lead to more personalized treatment approaches, optimizing efficacy and minimizing side effects. Additionally, efforts to reduce the cost of DAAs could improve accessibility, ensuring that more children worldwide can benefit from these life-saving medications.
